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1. Introduction 
Cardiovascular disease (CVD) is widespread in the modern world and represents one of the 
main causes of mortality (Levi et al., 2009). Increased blood cholesterol content (Hozawa, 
2011) and oxidative modification of low density lipoproteins (Vogiatzi et al., 2009) represent 
risk factors for the development of CVD. The right nutrition is considered effective in the 
prevention and treatment of CVD (Rudkowska & Jones, 2007). The results of 
epidemiological, clinical and experimental studies show that soy foods decrease blood 
cholesterol in individuals with hyperlipidemia, as well as mortality rates from CVD both in 
Asians and Caucasians (Anderson et al., 1995; Borodin et al., 2009; Messina & Messina, 
2003). Soy beans contain antioxidants that exert an antioxidant effect when people consume 
soy foods (Bertipaglia de Santana et al., 2008). This effect may be also beneficial for CVD 
patients. This review focuses on the discussion of modern data on antioxidant and 
hypocholesterolemic effects of soy foods, as well as on the potential role of soy foods in the 
prevention and treatment of CVD in Russia.  
2. Antioxidant effect of soy foods 
The antioxidants of soy beans are represented by isoflavones, tocopherols, ascorbic acid and 
some other compounds (Barnes, 2010; Borodin et al, 2001). When soy beans are processed 
into different foods the particular antioxidants content of the produced foods may change 
depending on the processing procedure (Xu et al., 2010) and storage conditions (Rau De 
Almeida Callou, 2010) and differ from the initial antioxidant content in the soy beans 
(Anderson & Wolf, 1995). However, antioxidants of soy beans are also present in soy foods. 
So, the consumption of soy foods is followed by the antioxidant effect (Bertipaglia de 
Santana et al., 2008; Borodin et al., 2001). Among the antioxidants of soy beans mainly it is 
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isoflavones that had attracted the attention of researches in explaining the health effects of 
consumption of soy foods (Barnes, 2010; Messina, 2010). Much less attention has been paid 
to the tocopherols and other soy antioxidants (Borodin et al., 2001; Mikoluc et al., 2009).  
2.1 Antioxidants of soy beans and some soy foods 
Table 1 shows the results of our measurements of some antioxidants content in the species 
of soy beans, planted in the Far East of Russia, and some locally produced soy foods.  
 


















Soy beans 580-3800 10-70 380 3.80 19 70 
Full fat 
soy flour 
580-3800 10-70 370 3.37 13 97 
Lipoxygenase 
soy flour 
580-3800 10-70 310 2.92 15 101 
Semi-fat 
soy flour 
370-2500 10-70 265 3.99 10 110 
Soy milk 30-175 9-50 21 3.47 Trace 15 
Tofu - - 124 4.17 Trace 51.7 
Table 1. Isoflavone, tocoferol, ǃ-carotene and ascorbic acid content of soy beans and some 
soy foods. Tocoferol and ǃ-carotene content was measured in the lipid extracts from soy 
beans and soy foods by colorimetric methods and ascorbic acid content was measured by 
titration of acidic extracts with 2,6-dichlorphenolindofenol.  * - data from Anderson R. & 
Wolf W. (Anderson & Wolf, 1995).  
The major antioxidants in soy beans are isoflavones and tocopherols. Total isoflavone 
content of soy beans (580-3800 μg/g of raw weight or 10-70 mmoles/mole of triglycerides) is 
1.5-10 times higher than such of tocopherol content (380 μg/g of raw weight or 3.8 
mmoles/mole of triglycerides). In different types of soy flour the content of these 
antioxidants is nearly the same as in soy beans. Isoflavone and tocoopherol content of soy 
milk and tofu is considerably less if expressed in μg/g or μg/mL of product. However, it is 
very similar to that of soy beans if expressed in mmoles/mole of triglycerides. Soy bean oil 
contains 3-4 molecules of tocoferols per 1000 molecules of triglycerides. Despite the fact that 
isoflavones are polar compounds, which are not soluble in oils, the formal calculation of the 
total isoflavone content in soy beans and soy foods as mmoles/mole of triglycerides shows 
that 10-70 molecules of isoflavones correspond to 1000 molecules of triglycerides. ǃ-carotene 
content of soy beans and soy flour is 20-30 times lower than tocopherol content and 200-300 
times lower than isoflavone content. Ascorbic acid content in  raw soy beans (70 μg/g) and 
soy foods (15-110 μg/g) is low and soy foods do not play any substantial role as a source of 
this vitamin for humans.  
Due to the high amounts of antioxidants soy beans and soy foods are resistant to oxidative 
modification. In the analyzed samples of soy beans and soy foods the primary products of 
lipid peroxidation, namely, dien conjugates and lipid hydroperoxides have been determined 
but their content was rather low – from 2 to 7 conjugated double bonds and less than 1 
hydroperoxide group per 1000 molecules of triglycerides (table 2).  
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Soy beans 1690 7.28 160 0.69 
Full fat soy flour 940 3.68 130 0.51 
Lipoxygenase soy flour 870 3.53 97 0.39 
Partly defatted soy flour 690 4.46 110 0.71 
Soy milk 26 1.77 14 0.95 
Tofu 122 1.77 34 0.97 
Table 2. Dien conjugate and lipid hydroperoxide content of soy beans and some soy foods. 
Dien conjugate and lipid hydroperoxide content was measured in the lipid extracts from soy 
beans and soy foods by the absorbance at 233 nm and by the ability to oxidize Fe2+ ions, 
respectively (Borodin et al, 2001).  
2.2 Antioxidant effect of soy milk in vitro  
It is easy to demonstrate the antioxidant effect of soy milk in vitro by its ability to inhibit the 
process of lipid peroxidation in a system containing fast oxidizing substrate, for example in 
liver microsomes (table 3). The rate of lipid peroxidation in liver microsomes consists of 
2.52±0.31 nmoles of malonic dialdehyde (MDA) min-1 mg-1 of phospholipids in the presence  
 





(nmoles of MDA min-1 
mL-1) 
AOA (%) Oxidizeability 
(nmoles of MDA min-1 
mL-1) 
Liver microsomes* 2.52±0.31 - 1.5±0.18 
Soy milk 0.48±0,18 57.3±9.3 2.80±0,09 
Caw milk 0.28±0,17 10.9±2.5 
(p<0,05)**
2.63±0,17 
Table 3. Oxidizeability and antioxidant activity of soy and cow milk at lipid peroxidation in 
liver microsomes. I mL of the incubation mixture contained 0.8 mǺ ascorbate (or 1mM 
NADPH); 0.2 mǺ sodium pyrophosphate; 50 mǺ tris-HCl buffer, рǻ 7.4.; 1 mg of 
microsome protein and 0.1 mL of milk. The time of incubation was 5 min for ascorbate-
dependent lipid peroxidation and 20 min for NADPH-dependent lipid peroxidation. Lipid 
peroxidation was initiated by the addition of Fe+2 ions in final concentration 2 μǺ. The 
reaction was stopped by the addition of 30% trichloracetic acid in final concentration 1.5 
mǺ. MDA – malonic dialdehyde. AOA – antioxidant activity. AOA was calculated by the 
ability of soy and caw milk to inhibit MDA accumulation in the incubation medium at the 
initiation of lipid peroxidation in liver microsomes (Borodin et al., 2001). MDA content in 
the incubation medium was determined by the color reaction with thiobarbituric acid (TBA-
test) (Borodin et al., 1993). Values are means ± SEM. * - oxidizeability of microsomes was 
expressed as nmoles of MDA min-1 mg-1 of microsome phospholipid; **- p values 
corresponds to the differences between the AOA of soy and cow milk.  
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of ascorbic acid and Fe2+ions being significantly higher than oxidizeability of soy- and caw 
milk (0.48±0.18 and 0.28±0.17 nmoles of MDA min-1 mL-1, respectively). In contrast to this in 
the presence of NADPH and Fe2+ ions soy milk and caw milk oxidize faster (2.80±0,09 and 
2.63±0,17 nmoles of MDA min-1 mL-1) than liver microsomes (1.5±0.18 nmoles of MDA min-1 
mg-1 of phospholipids). The difference between the oxidizeability of soy milk and caw milk 
in the presence of ascorbic acid and Fe2+ ions is not statistically significant. In the presence of 
NADPH and Fe2+ ions both types of milk oxidize at the same rate. It is interesting to note 
that in the presence of NADPH soy milk oxidize 5-times faster and caw milk 10-times faster 
than in the presence of ascorbate. The antioxidant effect of soy milk on ascorbate-dependent 
lipid peroxidation in liver microsomes is 5-fold higher than the effect of cow milk. To 
calculate the antioxidant effect of soy and caw milk on NADPH-dependent lipid 
peroxidation in liver microsomes seems impossible because the rate of the oxidation of 
microsomes is slower than the rate of oxidation of milk. The results obtained testify to the 
high antioxidant properties of soy milk, probably due to high isoflavone and tocopherol 
content. Because of this soy milk oxidizes rather slowly despite the high content of 
polyunsaturated fatty acids in its lipids (table 4).  
2.3 Fatty acid composition of soy- and caw-milk 
The lipids of caw- and soy milks are characterized by the following marked differences in 
fatty acid composition, which may be important for their dietary value for CVD patients 
(table 4). 1) total content of  saturated fatty acid in caw milk (63.8%) is 3,7 times higher than 
in soy milk (17.8%); 2) total monousaturated fatty acids content in caw milk is also higher 
and consists of 30,4% versus 21,5% in soy milk; 3) total content of polyunsaturated fatty 
acids (PUFA) in caw milk (61.2%) is 10,6 times higher than in the caw milk (5,7%); 4) the 
content of omega-3 PUFA, which is considered favorable for the prophylaxis of CVD 
(Saravanan et al., 2010), is 4.2 times higher in soy milk than in caw milk (8.53% versus 2.03%, 
respectively; 5) the fatty acid composition of the lipids in soy milk is less diversified than in 
cow milk. Short chain fatty acids (С<10) are not represented in the lipids of soy milk and 
represent minor components of caw milk; 6) the principal fatty acids of soy milk are 
polyunsaturated linoleic acid (18:2n-6) (52%), monounsaturated oleic acid (18:1n-9) (18%) 
and saturated palmic acid (16:0) (12%) while the main fatty acids of caw milk are saturated 
acids – palmitate (16:0) (25%) and stearate (18:0) (14%) and monounsaturated oleic acid 
(18:1n-9) (21%); 7) the specific minor fatty acids of soy milk are 18:3n3, 10:1n-9 and 22:0 and 
caw milk 4:0, 8:0, 10:0, 12:1, 14:1, 15:0-iso, 15:0-antyiso, 16:0-iso, 16:1n-9, 16:2, 17:0-iso, 17:1, 
18:1-trans (table 4). High content of PUFA in soy milk and especially of omega-3 family 
PUFA, represents an important dietary advantage of this milk compared to caw milk for the 
prevention and treatment of CVD. The striking feature of soy milk in comparison with cow 
milk is lower triglyceride and higher tocoherol and phospholipid content. As a result, the 
ratio phospholipids/triglycerides in soy milk is 3 times higher than in caw milk (Borodin et 
al., 2001), which  represents another advantage of soy milk for CVD patients. 
2.4 Antioxidant effect of consumption of soy milk in vivo  
The results presented above show that soy milk contains complex of antioxidants and 
reveals antioxidant effect both in vitro and in vivo. The consumption of soy milk is followed 
by an increase in the ǂ-tocoferol content in the blood (Borodin et al., 2001, 2003). It was 
therefore of interest to determine to what extent the antioxidant effect of soy milk may be 
attributed to ǂ-tocoferol? To answer this question we performed the following  study.  
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Fatty acids Cow-milk Fatty acids Soy-milk 
4:0 3.28   
6:0 2.02   
8:0 0.48   
10:0 2.22   
12:0 2.63 12:0 0.11 
12:1 0.10 14:0 0.22 
14:0-iso 0.19 15:0 0.06 
14:0 9.24 16:0 11.80 
14:1 0.69 16:1n-7 1.92 
15:0-iso 0.38 17:0 0.11 
15:0-antiiso 0.68 18:0 4.34 
15:0 1.20 18:1n-9 18.05 
16:0-iso 0.33 18:1n-7 1.32 
16:0 25.37 18:2n-6 51.88 
16:1n-9 1.21 18:2n-4 0.82 
16:1n-7 0.40 18:3n-6 0.73 
17:0-iso 0.56 18:3n-3 7.80 
16:2 0.52 20:0 0.32 
17:0 0.65 20:1n-9 0.20 
17:1 0.28 22:0 0.32 
18:0 14.18   
18:1n-9 21.14   
18:1n-7 4.51   
18:1-trans 2.07   
18:2n-6 2.60   
18:2n-4 0.60   
19:0 0.23   
18:3n-3 1.05   
18:4n-3 0.98   
20:0 0.21   
Table 4. Fatty acid composition of lipids of soy- and cow-milk (% from total fatty acids). 
Fatty acid composition of soy- and cow-milk was measured by the gas-liquid 
chromatography of methyl esters of fatty acids.  
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26 healthy young volunteers aged 17-19 years (16 females and 10 males) were recruited on a 
voluntary basis. The participants were informed in detail about the purpose, advantages 
and disadvantages of the study, and their rights and duties concerning their lifestyle. 
Informed consent from all participants was obtained in writing. The protocol was approved 
by the Amur State Medical Academy Ethics Committee according to the Helsinki 
Declaration on human studies. The subjects were assigned to two groups with similar age 
and gender. Participants in the first group received one glass of soy milk daily for 2 weeks. 
Participants in the control group received 5 mg of tocopherol acetate (pharmaceutical 
preparation of vitamin E) daily in the form of an oil solution. Exactly that amount of ǂ-
tocoferol is contained in one glass of soy-milk. The subjects were instructed to consume 
similar amounts of food from day to day and do not consume any vitamins or drugs within 
the study period. At the beginning and at the end of the study the samples of blood were 
taken and then the biochemical indices reflecting the state of lipid peroxidation were 
measured in blood serum. Results are presented in the table 5.  
Soy milk was well accepted by all subjects and there were no any complaints. At the 
beginning there were no significant differences in the values of the biochemical indices 
between the groups. At the end of the study the increase in the ǂ-tocopherol content in the 
control group from 9.2.0,71 to 10.80,74 mg/L was not significant (р>0.1). The 30% increase 
in the ǂ-tocopherol content in the group receiving soy milk from 7.8±0.44 mg/L at the 
beginning up to 10.6± 0.77 mg/L was statistically significant (p<0.005). The increase in ǂ-
tocopherol content in serum was characteristic for 11 participants of the group receiving 
soy-mil and only for 7 participants of the group receiving tocopherol acetate. Consumption 
of soy milk or tocopherol acetate for 2 weeks was followed by a 2-fold or 1,7-fold decrease of 
serum lipid hydroperoxide content, respectively (p<0.05). However, the decrease of the dien 
conjugate content from 31.25.0 μmoles/L to 22.52.1 μmoles/L was characteristic only for 
the experimental group but the changes were statistically insignificant (p>0.1). The 
consumption of soy milk or tocopherol acetate does not influence the content of TBA-
reactive substances and oxidizeability of serum. Thus, the consumption of both soy milk and 
tocopherol acetate for 2 weeks by young healthy people resulted in an antioxidant effect, 
manifested by a decrease in the lipid hydroperoxide content and an increase in the ǂ-
tocopherol content in blood serum, but the strength of the effect was higher in the group of 
persons receiving soy milk. The stronger antioxidant effect of soy milk was correlated with 
higher and statistically significant increase in the ǂ-tocopherol content in the serum of the 
participants. The results appear strange because both groups of participants received the 
same amounts of tocoferol - 5 mg daily. The only difference was the form of tocopherol. In 
soy beans and soy foods tocopherols are present in a free form, while the paharmaceutical 
preparation of tocopherol (vitamin E) is tocopherol acetate. In contrast to free tocopherols, 
tocopherol esters can not express an antioxidant effect because phenol hydroxyl, which is 
important for this effect, is blocked by fatty acid. This may be the reason for the weaker 
antioxidant effect of tocopherol acetate. The colorimetric method of determination of 
tocoferols is based on their ability to reduce Fe3+ ions. Tocoferol acetate is not able to reduce 
Fe3+ ions and therefore may not be determined by this method. To exert an antioxidant effect 
in humans and to be determined by the colorimetric method tocopherol acetate whould 
have to be first hydrolyzed by esterase. The other explanation for this finding would be 
worse intestinal uptake of tocoferol acetate when it is administered in the form of oil 
solution. 
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Indices Groups studied 
Treated with tocopherol acetate
(n=13) 




























































Table 5. The influence of soy milk and tocoferol acetate on the content of ǂ-tocopherol and 
lipid peroxidation products and oxidizeability of serum of young healthy persons. The 
methods of the measurements are indicated above in the legend to the tables 1-3. Values are 
means ± SEM. p values correspond to the differences between the values of the index in the 
indicated groups of persons (t-test for independent samples).  
3. Hypocholesterolemic effects of soy foods  
People, consuming soy foods, have lower blood cholesterol (Anderson et al., 1995; Devell et 
al., 2006; Zhan & Ho, 2005) and mortality rates from cardiovascular diseases (CVD) 
(Beaglehole, 1990; Messina & Messina, 2003). It was shown both in Asians (Ho et al. 2000; 
Nagata et al., 1998) and Westerners (Rosell et al., 2004; Teixeira et al., 2000; Tonstad et al., 
2002). Both soy protein and combination of soy protein with isoflavones are effective in 
reducing blood cholesterol (Dewell et al., 2006). In 1999 the Food and Drug Administration 
of the USA recommend daily consumption of 25 g of soy protein to control cholesterol 
content of blood (Food and Drug Administration, 1999). However, consumption of 25 g of 
soy protein a day may be not enough to low blood cholesterol level and recent meta-analysis 
showed that favorable results were observed only in the studies with high amounts of 
soybean protein (up to 60 g a day) (Reynolds et al., 2006) and there were no effects when the 
participants consumed 25 g of soy protein isolate (SPI) daily for 6 weeks or less (West et al., 
2006). These results led some AHA experts to question the effectiveness of soy protein in 
decreasing blood cholesterol (Sacks et al., 2006). From above it is possible to conclude that 
that the daily dose of soy protein should be at least 30 g and the duration of study should be 
more than 6 weeks to achieve favorable changes in lipid concentrations in blood. For longer 
studies, the problem of acceptability of test foods is very important. If the taste or smell of 
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foods was not acceptable, participants often failed to follow the study program. It is very 
common in  interventional studies with SPI that a significant proportion of participants do 
not finish the study. The poor acceptability of SPI to the subjects could have been the reason 
for the relatively short periods of the previous studies with SPI. The problem of acceptability 
of the test foods is particularly important for people who are not familiar with soy foods, for 
example for Russians.  
3.1 Test foods with soy- and milk protein for interventional studies  
Test foods for interventional studies with soy protein should meet both scientific demands and 
consumer's choice, but it is rather difficult to meet both requirements because they are 
contradictory. Two types of proteins are usually used in such studies: SPI for the experimental 
group of participants and milk protein casein for the control group. For scientific reasons, it is 
better to use pure proteins probably in the form of a drink because other ingredients, such as 
fats and carbohydrates (especially in high amounts) may substantially increase the energy 
content of the foods and influence the blood cholesterol level. However, water solubility of SPI 
and casein is low and drinks with these proteins have a rather bad taste and smell so they may 
not be consumed by the participants over a long period. Most previous studies did not include 
a sufficient description of the formulas for the test foods enriched with SPI and casein. The 
authors simply wrote: “The test proteins were incorporated into a variety of baked products 
and ready-to-mix beverages” (Teixeira et al., 2000).  
We felt it was impossible to prepare drinks with SPI and casein with relatively good taste 
and smell. To investigate the effect of SPI on blood cholesterol in Russian adults with 
moderate hyperlipidemia we developed SPI-enriched cookies in cooperation with food 
specialists (composition per 1 kg of cookies: wheat flour - 333g, SPI - 333g, margarine - 183g, 
sorbitol - 233g, egg - 33g, salt- 6,7g, baking soda - 3,3g, ammonia carbonate - 1,7g, energy 
value - 340 kkal in 100g). Thus, the protein content of a cookie was high while the energy 
content was rather low (340 kcal/100g) due to the use of sorbitol instead of sucrose. The 
daily total amount of cookies made up 30g in terms of protein content and was divided into 
2 or 3 servings throughout the day. SPI (FUJIPRO) was obtained from JILIN FUJI PROTEIN 
CO., LTD. China. Preparation of cookies with casein was difficult because of its low 
solubility in water and formation of glue-like structures. So, we used skimmed card (SMP – 
skimmed curd milk protein, protein content 18%, fat - 0.6% and carbohydrates - 1.5%) as a 
source of milk protein for the control group instead of casein powder. The composition of 
SMP-enriched cookies was identical to the composition of SPI-enriched cookies with the 
exception of test protein.  Skimmed curd was purchased from an authorized local provider. 
Picture 1 shows images of SPI and SMP-cookies.  
3.2 The influence of the two-month consumption of 30 g a day of SPI or SMP on blood 
lipids in Russians with moderate hyperlipidemia*  
*The results of this study had been published previously in the J. Nutr. Sci. Vitaminol. 
(Borodin et al, 2009).  
The aim of this study was to investigate the ability of SPI to decrease blood lipids in Russians, 
whose dietary habits and life-styles predispose them to low longevity, as a result of a high 
mortality rate from CVDs (Kharchenko et al., 1997). A cardiologist had elected 14 male and 39 
female Russians aged 32-67 years with elevated blood lipids and overweight on a voluntary 
basis and suggested them to become participants of the study. They were informed in detail 
about the purpose, the advantages and disadvantages of the study, and their rights and duties 
concerning their lifestyle. We instructed the subjects to follow their usual life and nutrition 
www.intechopen.com
 Antioxidant and Hypocholesterolemic Effects of Soy Foods and Cardiovascular Disease 
 
415 
styles, to minimize differences in energy intake from day to day, to maintain their body 
weight, and to avoid the use of lipid-lowering drugs throughout the study. The physical 
characteristics, nutrient intake, and physical activities of subjects were documented. The blood 
samples were taken after a lead-in period of 2-3 weeks. Samples of serum were frozen and 
analyses of lipids, GPT and GOT were performed. From the total number of subjects thirty (9 
males and 21 females) aged 32 - 64 years were selected on the basis of ability to follow the 
protocol. The inclusion criteria were overweight (BMI 25-34 kg/m2), fasting serum total 
cholesterol 240-330 mg/dL, non-HDL-cholesterol 150-280 mg/dL, HDL-cholesterol 40-70 
mg/dL, and triglycerides 100-280 mg/dL. The exclusion criteria were the presence of 
endocrine, liver, renal and gastrointestinal diseases. The protocol was approved by the Amur 
State Medical Academy Ethics Committee in accordance with the Helsinki Declaration on 
human studies. Informed consent from all participants was obtained in writing.  
 
  
Picture 1. SPI enriched cookies (left) and SMP-enriched cookies (right).  
The 30 subjects with hyperlipidemia were randomly assigned to two groups, consisting of 
15 persons each. These groups of subjects received either SPI cookies or SMP cookies for 2 
months. After a month washout period, the subjects received the opposite test food for 
another 2 months. So, we used a crossover design in this study, which has apparent 
advantages for studies with small groups of persons. Twenty-eight participants (19 females 
and 9 males) could complete the trial. Fasting blood samples were drawn before and after 
one moth and two months of the dietary treatments. Serum samples were frozen and 
analyzed for lipids, total protein and glucose concentrations, GPT and GOT activities by the 
conventional laboratory diagnostic methods. A nutrition survey was done every month, 
including the wash-out period, for 3 non-consecutive days (2 week days and 1 weekend 
day) by the 24-hour recall method. 
The baseline characteristics of the subjects are shown in the table 6.  
Subjects were characterized by overweigh with average BMI 29.0±3.87. There were some 
differences in energy intake and physical activity between male and females participants. 
The values of serum total cholesterol, non-HDL-cholesterol, HDL-cholesterol, and 
triglycerides were typical for moderate hyperlipidemia. Both the SPI cookies and SMP 
cookies were well accepted by the majority of the subjects and twenty-eight subjects 
successfully completed the trial.  
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Index Males Females 
Number of participants 9 21 
Physiological indices    
Age (years) 51±2 50±2 
Weight (kg) 87.2±3.8 77.6±2.4 
Height (cm) 173±2 164±1 
BMI 29.6±1.2 28.7±0.9 
Energy consumption (kcal per day) 2022±218 1409±93 
Nutrients intake (g per day):   
Proteins 107,0±6,7 78,9±5,9 
Fats 80,0±7,4 52,5±2,9 
Carbohydrates 272,0±20,0 152,7±8,9 
Steps per day 9397±1373 8569±642 
Biochemical indices   
Total Cholesterol (mg/dL) 301±26 247±7 
HDL-Cholesterol (mg/dL) 54±3 63±4 
Non HDL-Cholesterol (mg/dL) 247±25 214±9 
Triglycerides (mg/dL) 255±33 183±30 
Glucose (mg/dL) 80±9 94±8 
Total protein (g/L) 78±2 77±1 
GOT (U/L) 20±1 20±2 
GPT (U/L) 16±2 18±3 
Table 6. Characteristics of the participants at baseline (from Borodin et al., 2009). Values are 
means ± SEM except the number of participants.  
The participants consumed similar amounts of food from day to day within the study 
period. There were no significant differences in BMI, energy, protein, fat and carbohydrate 
intakes, and physical activity throughout the trial (table 7).  
The changes in serum lipid, glucose and total protein concentrations and GPT and GOT 
activities before, within  and after the consumption of the test foods are shown in the table 8.  
In agreement with the results of the previous studies (Reynolds et al., 2006), in our study 
one-month SPI consumption was not enough to decrease blood lipids and only triglycerides 
in blood serum decreased by 10%, while serum cholesterol did not change. In contrast to 
this, the consumption of SPI for 2 month was followed by the significant changes in serum 
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lipids, namely, by the reduction of total-cholesterol by 17 mg/dL, of non-HDL-cholesterol 
by 22 mg/dL, and of triglycerides by 31 mg/dL, and by the increase of HDL-cholesterol by 
5,1 mg/dL (table 8). The observed effect of consumption of 30 g a day of SPI should be 
considered as strong, bearing in mind the results of the recent meta-analysis of the effect of 
soy protein supplementation on serum lipids, which shows that the overall pooled net effect 
of soy protein supplementation on serum lipids was -5.26 mg/dL for total-cholesterol, -4.25 
mg/dL for LDL cholesterol, 0.77 mg/dL for HDL cholesterol and -6.26 mg/dL for 
triglycerides (Reynolds et al., 2006). The important results of our study are the clear increase 
in HDL-cholesterol concentration and clear decrease in non–HDL concentration (table 8). In 
previous studies, even those with a high SPI administration, only a few studies revealed 
significant changes in the HDL-cholesterol concentration (Sacks et al., 2006). The established 
ability of SPI to decrease serum triglycerides and glucose indicates that soy foods may be 
useful in the prophylaxis and treatment of metabolic syndrome. The consumption of the 
same amount of SMP did not induce any changes in serum lipids and glucose 
concentrations.  
 
Indices Groups Initial Values After 1 months After 2 months 
BMI SPI 28.7±0.7 28.5±0.7 28.8±0.7 
SMP 29.2±0.7 29.0±0.7 28.9±0.7 
Energy intake 
(kcal/day) 
SPI 1713±110 1644±115 1670±121 
SMP 1574±92 1612±97 1555±138 
Nutrients intake 
(g/day): 
    
Protein SPI 86.9±4,8 89.9±4.8 88.1±4.6 
 SMP 82.4±3.0 88.4±3.0 81.7±3.5 
Fat SPI 62.1±3.3 63.1±3.3 67.4±3.8 
 SMP 56.6±2.1 58.6±2.1 57.0±3.0 
Carbohydrate SPI 195±7 190±10 182±12 
 SMP 185±9 182±9 172±10 
Activity* 
(steps/day) 
SPI 8757±955 8629±845 8710±640 
SMP 8910±805 8727±910 9157±702 
Table 7. BMI, energy and nutrient intakes and physical activity of the participants at 
baseline and after 1 and 2 months of the dietary treatments (from Borodin et al., 2009).  
* - Physical activity of the subjects was monitored by the measurement of the number of 
steps per day with a help of pedometer (Omron HJ-005-E, China). Values are means ± SEM. 
Total number of participants in each pooled group is 28. 
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Indices Groups Initial Values After 1 month After 2 months 
Total Cholesterol 
(mg/dl) 
SPI 280±7 281±10 263±9** 
SMP 277±9 282±10 272±9 
HDL-Cholesterol 
(mg/dL) 
SPI 57.4±2.5 60.2 ±2.6 62.5±2.9*** 
SMP 59.3±3.3 60.1±2.4 56.6±2.6 
Non HDL-Cholesterol 
(mg/dL) 
SPI 223±7 221±10 201±8.8*** 
SMP 219±10 222±10 215±9 
Triglycerides 
(mg/dL) 
SPI 204±23 183.3±2* 173±16* 
SMP 192±17 193±20 201±17 
Glucose 
(mg/dL) 
SPI 85.8±4.7 83.4±3.0 79.0±3* 
SMP 87.8±5.5 86.1±4.8 88.6±3.6 
Total protein 
(g/L) 
SPI 78.0±1.0 78.3±0.8 78.9±0.8 
SMP 76.2±0.8 78.0±0.7 77.6±1.1 
GOT 
(U/L) 
SPI 22.1±2.4 20.8±1.7 22.2±2.1 
SMP 17.2±1.4 20.7±1.4 18.9±1.7 
GPT 
(U/L) 
SPI 22.6±3.1 18.3±2.6 21.1±1.9 
SMP 16.5±1.7 16.4±1.7 18.9±1.9 
Table 8. Serum lipid and glucose  concentrations and GOT and GPT activities at the 
beginning and after 1 and 2 months of the dietary treatments (from Borodin et al., 2009). 
Values are means ± SEM. Total number of participants in each pooled group is 28. * - p<0.05; 
** - p<0.01; *** - p<0.005. P values correspond to the deference between the initial values of 
the index  and values after 1 or 2 month (t-test for dependent samples) 
We see at least three reasons of the observed favorable effects of consumption of SPI in this 
study. The first reason may be the relatively long administration of the test foods and use of 
crossover design. In nutrition interventional studies proper care of the subjects is very 
important and because of this it is not easy to increase the number of participants. Inter-
individual variances are usually large and therefore a large number of subjects is required to 
have significant effects in a parallel-group study, while a relatively small number of 
participants is sufficient for a study with crossover design because the inter-individual 
differences are thereby minimized. A review paper by AHA shows that most studies with 
crossover design were less than 6 weeks (Sacks et al., 2006). In our study, the results at 1 
month were not effective but those at 2 months were effective, suggesting that only long 
studies may be able to decrease blood lipids of hyperlipidemic Russians at 30 g SPI a day. 
The second reason for the favorable results may be the good acceptability to the subjects of 
the test diets. Sustainability is always required for these types of studies to show the 
expected results. The reason for the relatively short periods of the previous studies 
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mentioned above might have been the poor acceptability and poor sustainability of SPI to 
the subjects. SPI at 30 g a day may be easy for Asians to accept but not for Westerners and 
Russians. For this reason, we developed well-accepted test-foods with a high SPI content. 
The intakes of energy, proteins, fats and carbohydrates were similar at all periods of study: 
in the initial period, during the first and second months and at the washout period, which 
may also mean that the cookies were well accepted. The third reason for the favorable 
results may be the level of hyperlipidemia in our subjects. As reviewed by Anderson et al. 
(1) the cholesterol-lowering effect of SPI was observed more clearly in subjects with high 
serum Total- and LDL-cholesterol concentrations than in those with normal and low lipid 
concentrations. Our inclusion criteria were overweight (BMI 25-34 kg/m2), fasting serum 
total cholesterol 240-330 mg/dL, non-HDL-cholesterol 150-280 mg/dL; HDL-Cholesterol 40-
70 mg/dL, triglycerides 100-280 mg/dL.  
Conclusion  
Consumption of the low-energy SPI-enriched cookies (30 g of SPI a day) for 2 months with a 
crossover design confirmed the favorable effects of SPI on serum lipids in Russians with 
moderate hyperlipidemia.  
4. CVD, soy and soy foods in Russia  
In the 90-th of the last century the situation with the health of Russian people drastically 
deteriorated and CVD had became the main reason of mortality. Above we discussed the 
antioxidant and hypocholesterolemic effects of soy foods and our personal results, showing 
the effectiveness of soy foods in the decreasing of blood cholesterol in Russians with 
moderate hyperlipidemia. In the last part we will focus attention on the epidemiology of 
CVD in modern Russia, dietary habits and lifestyle of Russians, which predispose high 
mortality rate from CVD, and on the possibility of use of soy foods for the prevention and 
treatment of CVD in Russia.  
4.1 Epidemiology of CVD in Russia  
An epidemiologic feature of the present Russia is the high mortality rate from CVD. 
According to the WHO Statistical Information System Mortality Database, the mortality rate 
per 100,000 from CVD in Russian adults under 65 years increased from 141-161 in 1986-1991 
to 233-251 in 2001-2005 (WHO Statistical Information System Mortality Database). The rates 
were similar to those in the USA (241.8 and 244.4 for males and females, respectively) and 
England (263 and 235) and higher than those in Japan (136 and 138) and France (172 and 
176) (WHO Statistical Information System Mortality Database). The average lifespans of 
Russians in late 1990s were only 58 years for males and 72 for females, while they were 79 
and 86 for Japanese, 75 and 80 for Americans, and 77 and 81 for French individuals (UN 
Demographic Yearbook 2004). The dietary habits and lifestyle of Russians, namely high 
consumption of saturated fats (Solodkaia et al., 1998) and abuse of alcohol (Leon et al., 2007), 
associated with excessive body mass (Konstantinov et al., 2002), predispose individuals to 
short longevity as a result of a high mortality rate, especially from CVDs (Kharchenko et al., 
1997), which is characteristic for the present-day Russians. Therefore, soy foods may be 
helpful for Russians in the prevention of CVD. Due to climate conditions, Russia is able to 
produce abundant soybeans but the consumption of soy foods by Russians is very limited 
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partly because of the low quality of the soy foods produced. Soy foods in Russia are used 
very infrequently in the treatment and prophylaxis of CVD in contrast to the Asian and 
European countries and USA.  
4.2 Soy planting and soy foods in Russia  
Initially, soybean was brought to Russia from northeastern China. Currently, soybeen is 
planted in the Far East of Russia (the Amur region and Prymorie), the Altai region and in 
the Kuban territory near the Black Sea. (picture 2).  
 
 
Picture 2. Soy planting in Russia. The regions farming soya are colored in turquoise 
(blue/green).   
Soybean is also planted in some other regions but the crop is small. The annual total crops of 
soyben in Russia makes up nearly a million metric tons which is very little in comparison 
with the main producers of soyben in the world. The All Russia scientific research institute 
of soya is based in the administrative center of Amur region Blagoveshchensk 
(http://www.amur.ru/~seray/index.html). The main task of this institute is the creation of 
the new species of soya, adapted to the local climatic condition, and the farming techniques 
of planting soya in these conditions. In Russia, soya traditionally processed into oil, flour 
and feeds. Soy flour is often associated with meat products – sausage, cutlet etc. One of the 
main obstacles in the promotion of soy foods in Russia is the image of soy products that, in 
the opinion of Russians, is not as foods for human but as feed for animals. The other 
obstacle is association of soya with genetically modified foods. Our 15-year long experience 
of promotion of soy foods in Russia as healthy foods shows that strong informational 
support from medical specialists is necessary to create a positive image of these foods in 
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Russian people. This informational support should be constant and prolonged. Our 
experience of promotion of soy foods in Russia with a help of specialists from Japan (Fuji Oil 
co.) shows that when Russian people have a chance to taste modern soy foods produced in 
Japan, they highly praised these foods and express desire to consume them (picture 3).  
 
 
Picture 3. Promotion campaign of the Fuji Oil Co (Osaka, Japan) in Russia (2005-2007 years) 
The visit to the milk plant “Alev” (up left) and the  conference with the mass media, medical 
specialist and cookery experts (up right) in Ulianovsk region; soy field in Amur region 
(bottom left); meeting with the participants of the study in the biochemistry department of 
the Amur State Medical Academy –(bottom right). 
The campaign of promotion of soy foods had been initiated in Russia in the second part of 
the 1990s. Many enterprises producing oriental soy foods like soy milk and bean curd– tofu 
as well as textured soy protein – have flourished. However, the vast majority of these 
enterprises used just simple equipment and the taste of those products was not good for 
Russians. As a result, the society lost interest in soy foods. To revive this interest, it is 
necessary to begin production of good quality soy foods in Russia and request for help from 
medical specialists in explaining the healthy properties of soy foods to Russian people as 
was done in European countries and the USA.  
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